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Background: Several studies in recent years have evaluated Health Related Quality of Life (HRQoL) of patients with
primary hyperparathyroidism (PHPT). No disease specific questionnaires are available to assess the impact of the
disease. The aim of this research is to describe the development of a new disease specific Quality of Life (QoL)
questionnaire for use specifically with PHPT patients.
Methods: A conceptual model was developed describing the impact of the disease and its symptoms on QoL
domains. A literature review was conducted to identify the most relevant domains. A focus group with experts was
used to validate the domains; 24 patients were also interviewed to complement the information from the patient’s
perspective. A content analysis of the interviews was performed to identify items related with the impact of the
disease, leading to PHPQoL-V.1 which was presented to a sample of 67 patients. Reliability was assessed by
Cronbach’s coefficient alpha and item-total score correlations. Validity was assessed by a factor analysis performed
to determine the number of domains. Rasch analysis was carried out in order to refine the questionnaire items.
Results: 259 items were extracted from the interviews that were subsequently reduced to 34 items. Cronbach’s
coefficient alpha was 0.92. The factor analysis extracted two domains (physical and emotional). After Rasch analysis
the questionnaire PHPQoL-V.2 kept 16 items (9 physical and 7 emotional). The questionnaire was developed in a
Spanish population and the final version was translated to English through translation and back-translation.
Conclusion: The first disease specific HRQoL questionnaire for PHPT patients (PHPQoL-16) has been developed.
Validation studies designed to assess measurement properties of this tool are currently underway.Introduction
Primary hyperparathyroidism (PHPT) is an endocrine dis-
ease characterized by hypercalcemia attributable to au-
tonomous overproduction of parathyroid hormone (PTH).
Therefore PHPT, is often detected by routine serum cal-
cium measurement [1]. Poor control of elevated calcium
levels can increase the risk of mortality due to cardiovas-
cular, gastrointestinal, nervous, or kidney disorders or
problems affecting bones and muscles [2]. In eight out of* Correspondence: SWebb@santpau.cat
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reproduction in any medium, provided the orten cases, the cause is a solitary, benign tumor (chiefcell
adenoma) [3]. The prevalence of PHPT increases with age
and is greater in women than in men; 80% of patients are
apparently asymptomatic [4,5].
The diagnostic and therapeutic approaches to PHPT
have changed in recent decades, but not without contro-
versy. Prior to the 1970s, diagnosis was based purely on
symptoms, meaning that the disease was only detected in
symptomatic patients. The diagnosis of asymptomatic
PHPT only became possible with the availability of bio-
chemical tests that made it possible to test serum calcium
levels and PTH [6]. Current PHPT treatment varies
according to whether or not a patient has symptoms; this
is reflected in different guidelines and consensus state-
ments [7]. These guidelines suggest that all patients with
confirmed PHPT and who present specific symptoms ortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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In addition, in some studies, surgical treatment has been
associated with significant improvements in neuropsycho-
logical symptoms such as anxiety, depression, and mood
swings [8-12], and HRQoL [13]. Improvement is particu-
larly significant in patients with symptoms of depression
and anxiety before surgery [14]. However, the benefit of
surgery in terms of improving HRQoL in asymptomatic
patients or in patients with minor symptoms is not so
clear [15]. The most common pharmacologic treatment
for apparently asymptomatic patients or patients who are
not eligible for surgery are bisphosphonates, estrogens,
vselective estrogen receptor modulators (SERMS), and
calcimimetics [7].
Few studies have analyzed the impact of PHPT on
HRQoL [16-19] and no disease specific questionnaires
was available. A questionnaire specifically designed to as-
sess the impact of symptoms on the emotional, social, and
physical well being of PHPT patients would be useful to
assess the impact of the disease and its treatment on
patients’ HRQoL.
The aim of this study is to present the results of the
development process of a disease specific HRQoL ques-
tionnaire for use in PHPT patients.
Material and methods
According to FDA guidelines related to patient-reported
outcome measures [20], the conceptual framework wasPHPT patient
Psychological symptoms: anxiety, depression, 














Figure 1 Conceptual framework.established for the development of the questionnaire
(Figure 1). A HRQoL specific questionnaire for PHPT
should reflect the impact of PHPT on patients, and should
be able to quantify the impact of physical and psycho-
logical symptoms. The ability of the questionnaire to
reflect the impact of psychological symptoms was consid-
ered a key issue, as these symptoms are more difficult to
identify by the endocrinologist, especially in patients who
declare not to have any symptoms. In addition, it was also
considered important to develop a questionnaire that took
into account the relationship between symptoms and their
impact on different domains of a patient’s life (psycho-
logical, social, physical, activities of daily living and en-
ergy/vitality). Considering all these aspects, the starting
point was the development of a specific PHPT HRQoL
questionnaire that would provide physicians with a tool to
gain knowledge on the impact of PHPT on the patient’s
daily life.
The HRQoL questionnaire for patients with PHPT
was developed in three phases, namely generation, selec-
tion, and reduction of items [21-23].
Item generation
The first step was to review studies and questionnaires
dealing with HRQoL in PHPT included in MEDLINE in
the past 10 years. The information obtained was used to
identify topics and domains related to HRQoL and










ical symptoms: fatigue, insomnia, polyuria, 
abdominal pain, sickness
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one specialist in HRQoL questionnaires development)
answered a semi-structured questionnaire in order to
validate the information obtained from the literature
review and identify those aspects they believed have an
impact on patients’ life. Thereafter a Focus Group was
organized with the same experts in order to reach a final
consensus on the most important domains to be in-
cluded in the final questionnaire. A Focus Group allows
information to be collected through group interaction
on a specific topic; giving rise to more information than
that obtained from individual interviews [24].
Item selection
In a second step, the resulting information on the most
important domains identified by the experts was then
used to create a semi-structured interview to identify
which items had the greatest impact on patient’s daily
life. A psychologist specializing in the development of
patient-reported outcomes interviewed 24 patients with
confirmed diagnosis of PHPT using this semi-structured
interview. PHPT was diagnosed using clinical and bio-
chemical data (hypercalcemia and elevated PTH after
ruling out other causes of hypercalcemia). The inter-
views, which lasted between 30 and 45 minutes, were all
audio-recorded and subsequently transcribed with the
patients’ consent. The transcribed interviews were then
used to extract items that indicated negative impact for
each of the HRQoL domains analyzed.
An initial analysis and review of the content of the
extracted items was performed by two psychologist to
identify items that were considered inappropriate, re-
dundant, or ambiguous. These items were removed from
the item list. The remaining items were then reworded
according to HRQoL expert opinion to produce a pre-
liminary list of questionnaire items.
Each item was critically evaluated by the same five ex-
perts for clarity (ease of understanding by the patient),
importance (relevance in terms of evaluating the impact
of PHPT on HRQoL) and frequency (number of cases in
which PHPT patients used the expression) [22,25,26].
The experts scored each item on a Likert-type scale ran-
ging from 1 (not very clear/important/frequent) to 5
(very clear/important/frequent). Based on the scores
assigned by the experts, items with a mean score of over
2.75 (25th percentile) were judged to be very clear; a
score of over 2 was considered to be very important and
very frequent (50th percentile in both cases). Items
which did not comply with the following percentiles
were removed: frequency × importance <50th percentile
plus importance <50th percentile; frequency × import-
ance <50th percentile plus frequency <50th percentile
and clarity <25th percentile. In the case of clarity, items
were removed when the problem was related to theconcept rather than the wording. Other content analysis
aspects were taken into consideration in the item reduc-
tion based on the judgment of three HRQoL experts.
Item reduction
The identified items were then assembled into a question-
naire format (PHPQoL-V.1, with 34 items) (see ‘PHPQoL-
V.1 (PHPQoL-34) subsection). A group of 67 active PHPT
patients were asked to complete the PHPQoL-V.1 ques-
tionnaire (pilot study). This group of patients did not in-
clude the 24 patients who were interviewed previously.
For each item, they were instructed to choose the option
(always, often, sometimes, almost never, never) that better
reflected their daily life. Data were also collected on age,
gender, history of surgery for PHPT (yes/no) and kidney
stone treatment, and fractures in the past two years.
PHPQoL-V.1 (PHPQoL-34)
In the last month,…
1. I’ve felt tired or fatigued
2. I’ve felt sleepy after getting up in the morning and
it’s been hard to get going
3. I’ve felt weak
4. I’ve found it difficult to walk for a long time
5. I’ve noticed that I get short of breath when I walk
quickly
6. I’ve had difficulty going up and down stairs
7. I’ve been irritable
8. I’ve felt depressed
9. I’ve been down
10. I’ve been sad
11. I’ve been in a bad mood
12. I’ve slept well
13. I’ve woken up during the night
14. I’ve had difficulty falling asleep
15. I haven’t been able to remember things
16. I’ve had difficulty remembering how to do routine
activities (e.g., cooking)
17. I’ve found it hard to concentrate
18. I’ve been worried when I think about my illness
19. I’ve been worried, not only about
hyperparathyroidism but also its complications
20. I’ve been worried that I might need an operation
21. I’ve had kidney stones
22. I’ve had stomach problems such as burning or
gastritis
23. I’ve been constipated
24. I’ve had back pain
25.My bones and/or joints have ached
26. I’ve been able to carry out my activities as normal
27. I’ve restricted some leisure activities because of the
symptoms of the illness
28. The illness has limited what household chores I do
Table 1 Sociodemographic and clinical characteristics of
the 67 patients who took part in the pilot studyof the
PHPQoL-v.1 questionnaire
Sociodemographic characteristics
Mean age (years), ±S.D. 59.2 ± 13.4
Female sex, n (%) 46 (69.7%)
Clinical variables
Surgery (yes), n (%) 31 (47.7%)
No treatment for kidney stones, n (%) 49 (74.2%)
No bone fractures in the past two years, n (%) 65 (100%)*
* This percentage reflects all patients that answered this variable
(65 of 67 patients).
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the future (such as holidays,…)
30. I’ve stopped doing things due to fear they would
make my illness worse
31. I’ve stopped doing things with friends because of
my illness
32. I’ve stopped working because of the illness
33. The illness has prevented me from working
34. I’ve noticed I find it more difficult to concentrate at
work than before
Results of the pilot study were analyzed using Classical
Test Theory (CTT) [27] and Item Response Theory
(ITR) [28], and specifically on the Rasch analysis [29,30].
Using the CTT approach internal consistency (correl-
ation of each item with total score, >0.7 theoretical)
and reliability (Cronbach’s alpha, >0.7 theoretical) were
assessed. Exploratory factor analysis was used to identify
domains based on factor loadings. The total possible score
on the PHPQoL-34 range from 34 (worst possible
HRQoL) to 170 (best possible HRQoL). In order to facili-
tate interpretation of scores, these were normalized to a
scale of 0 to 100, with higher scores indicating better
HRQoL, using the following formula:
P100 ¼ 100= pmax−pminð Þ½   preal−pminð Þ
The Rasch model specifies that an individual’s answer
to an item is the result of an interaction between the
position of the item in the construct (calibration) and
that of the individual (score). The model constructs a
line in which each item is positioned and provides fit
statistics to indicate how well an item describes the
questionnaire’s answer. The analysis was performed
using BIGSTEPS software, version 2.7.3. The term meas-
urement is a measure of the difficulty of each item (a
negative measurement indicates greater difficulty). The
most common statistics used in this model are infit and
outfit statistics (the information-weighted average of the
squared standardized deviation of observed score with
respect to expected score). Items with an infit or outfit
mean-squares value of over 1.4 or less than 0.6 were
excluded, as were items with a separation index of 1 for
each domain [31]. Successive Rasch analyses were
performed on each domain until all the items showed
satisfactory fit.
The final Spanish version of the questionnaire was ac-




Our literature search retrieved 64 studies on HRQoL in
PHPT; of these, 16 were selected for analysis of the mostrelevant items related to the impact of PHPT on daily life.
The rest of studies were excluded because they were com-
parative studies of pharmacological treatments or because
the measures used to evaluate HRQoL were not clear.
Twenty-two items were chosen, including weakness, anx-
iety, depression, insomnia, apathy, lack of concentration,
pain (muscle, bone, and joints), mood swings, loss of appe-
tite, and digestive problems (vomiting, nausea). The differ-
ent items were assigned to the following HRQoL domains:
physical, emotional, social functioning, daily activities,
symptoms, cognitive function, perceived health, sexual
function, energy/vitality, and pain.
Item selection
In total, 259 items considered to be relevant were
extracted from the transcriptions of the interviews
conducted in a group of 24 patients. Items considered to
be redundant, ambiguous, or inappropriate were excluded.
The number of items was reduced to 52 and reworded to
form a suitable questionnaire items. These items were
assessed by the group of experts, and those items that did
not meet the criteria mentioned in the “Item Selection”
section of “Material and Methods” were removed. The
total number of items remaining after the qualitative ana-
lysis conducted by the HRQoL experts was 34.Item reduction
The PHPQoL-V.1 ( see ‘PHPQoL-V.1 (PHPQoL-34) sub-
section) was presented to a group of 67 PHPT patients
(Table 1). Their mean (± SD) age was 59.2 (±13.4) years,
69.7% were women and 52.3% had a history of surgery
for PHPT.
The response rate was 80.9%. Most frequently un-
answered items were 32, 33, and 34, all related to work-
ing life.
Internal consistency as measured by Cronbach’s alpha
was 0.96 for the 34 items.
The mean normalized score obtained by the patients
on the PHPQoL-V.1 was 63.2 ±19.70.
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(items 16, 29, 30, 31, 32, and 33 of PHPQoL-v1, see
‘PHPQoL-V.1 (PHPQoL-34) subsection) were elimi-
nated. In total, six items were removed in this phase.
The remaining 27 items were subjected to exploratory
factor analysis, which yielded two major domains
explaining 51.5% of the total variance. The first domain
explained 44.5% of the variance while the second do-
main explained 7%. All of the items that contributed to
each of the domains had a factor loading of at least 0.4;
item 10 (I’ve been sad’) had a similar loading on both
factors but was included in the second one due to its
similarity to the other items in this domain. None of the
items in either of the two domains had a factor loading
of less than 0.4 and were therefore not removed.
Thereafter, the Rash analysis was performed for each
one of the domains. The Rasch model lists the items in
relation to severity and selects the items according to
adjustment to the model, redundancy, discriminant val-
idity and content.
Following the application of Rasch analysis (Table 2),
the number of items in the first domain was reduced
from 12 to 11; item 6 (I’ve had difficulty going up and
down stairs) was removed as it had an infit value of over
1.4. Overlapping items were assessed by the expert
group with the aim of retaining just one item per level
of impact. In the case of item 1 (I’ve felt tired orTable 2 Summary of Rasch analysis results for the physical an
Physical functioning domain (factor 1) (PHPQoL-9)
Item no. Item
2 I’ve felt sleepy after getting up in the morning and it’s been
26 I’ve been able to carry out my activities as normal
27 I’ve restricted some leisure activities because of the symptom
24 I’ve had back pain
5 I’ve noticed that I get short of breath when I walk quickly
25 My bones and/or joints have ached
28 The illness has limited what household chores I do
4 I’ve found it difficult to walk for a long time
3 I’ve felt weak
Emotional functioning domain (factor 2) (PHPQoL-7)
Item no. Item
17 I’ve found it hard to concentrate
34 I’ve noticed I find it more difficult to concentrate at work tha
12 I’ve slept well
19 I’ve been worried, not only about the illness but also its com
13 I’ve woken up during the night
8 I’ve felt depressed
7 I’ve been irritablefatigued) and item 24 (I’ve had back pain), it was de-
cided to retain item 24 as back pain is a common prob-
lem in PHPT and is also associated with a higher
incidence of hip fracture [33,34]. Furthermore, the con-
tent of item 1 was covered by items 3 (I’ve felt weak)
and 4 (I’ve found it hard to walk for a long time).
In the Rasch analysis of the second domain, five items
were removed as they were outside the limits established
for infit and outfit values. Items 7 (I’ve been irritable)
and 14 (I’ve had difficulty falling asleep) overlapped and
it was decided to retain item 7 as irritability had been
mentioned frequently by the patients interviewed. Fur-
thermore, sleep-related problems were already covered
by items 12 and 13. Likewise, in the case of items 8 (I’ve
felt depressed) and 18 (I’ve been worried when I think
about the illness), it was decided to retain item 8 as the
concept of worry was covered by item 19.
Item 16 was retained based on the results of the Rasch
analysis but the option not applicable was added to the
response categories, as the item was only applicable to
patients who were working.
After applying Rasch analysis in each domain, the total
number of items of the questionnaire was 16 (PHPQoL-
V.2) (see ‘PHPQoL-V.2 (PHPQoL-16) subsection); 9
items corresponded to the first domain (PHPQoL-9) and
7 items to the second domain (PHPQoL-7). Based on
the content of the items included in each domain, thed emotional functioning domains
Measure Error Infit Outfit
hard to get going 0.01 0.14 1.36 1.29
−0.89 0.15 1.02 1.29
s of the illness −1.04 0.16 1.21 1.14
0.72 0.14 1.19 1.18
−0.33 0.15 1.18 1.06
1.15 0.015 1.18 1.06
−0.74 0.15 1.02 0.90
0.25 0.14 0.88 0.89
0.15 0.14 0.62 0.65
Measure Error Infit Outfit
−0.17 0.14 1.28 1.24
n before −0.73 0.16 1.19 1.04
−0.51 0.15 1.13 1.08
plications 0.25 0.14 1.09 1.06
0.80 0.14 0.85 0.90
0.15 0.14 0.84 0.83
0.05 0.14 0.81 0.79
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tioning domain while the second one (PHPQoL-7) was
labeled as the emotional functioning domain.PHPQoL-V.2 (PHPQoL-16)
Over the last 4 weeks and due to calcium problems, …
1. I've felt sleepy after getting up in the morning and
it's been hard to get going
2. I've felt weak
3. I've found it hard to walk for a long time
4. I've noticed I get short of breath when I walk
quickly
5. I’ve had back pain
6. My bones and/or joints have ached
7. I've found it difficult to carry out my daily activities
8. I've restricted some of my leisure activities
9. I've restricted what household chores I do
10. I've been irritable
11. I've felt depressed
12. The illness has stopped me from sleeping well
13. I've woken up during the night
14. I've found it hard to concentrate
15. I've been worried, not only about the illness but also
its complications
16. I've noticed I find it more difficult to concentrate at
work than before
The correlations between the mean overall score
obtained on the PHPQoL-16 and on each of the do-
mains were over 0.90 and higher than the cutoff of 0.70.
The correlation between the mean scores obtained on
the PHPQoL-V.1 and the PHPQoL- V.2 was 0.98
(Table 3).Table 3 Correlation between PHPQoL-V.2 (16 items),
PHPQoL-9 (physical functioning), PHPQoL-7 (emotional









P < 0.001 P < 0.001
N = 61 N = 61
PHPQoL-V.1 (34 items) 0.98 0.93 0.91
P < 0.001 P < 0.001 P < 0.001
N = 55 N = 55 N = 55Table 4 shows a summary of the most relevant results
obtained for the initial 34- item (PHPQoL-V.1) and the
reduced 16-item versions (PHPQoL-V.2).
There were statistically significant differences between
overall scores when analyzed by gender, with women
scoring lower than men (p < 0.01). We also observed
worse HRQoL with increasing age, but this did not reach
statistical significance (p = 0.52). There were no signifi-
cant differences in scores depending on whether or not
the patients had undergone surgery (p = 0.074) or had
been treated for kidney stones (p = 0.23). None of the
patients reported fractures in the past 2 years.
The PHPQoL-v.2 was translated by two professional
(bilingual) translators with experience in translating
HRQOL questionnaires; in a consensus meeting both
translations were compared with each other and with
the original Spanish version. This version was then inde-
pendently translated back into Spanish to ascertain
equivalent significance in both languages.
Discussion
We have developed a disease specific HRQoL question-
naire for PHPT patients using classical test theory and
item response theory [22,23]. The first version composed
of 34 items was reduced resulting in a final version of
the question containing 16 items across two domains:
physical and emotional. The results suggest the ad-
equacy of the 16-item questionnaire for evaluating in a
valid and reliable way HRQoL of patients with PHPT.
The PHPQoL questionnaire has been specifically
designed to be used with those patients with PHPT. It is
designed to quickly assess the impact of the emotional/
neuropsychological and physical aspects of the disease that
can highly affect patients’ lives, but that are difficult to
quantify in a fast, standardized manner in routine clinical
practice. Furthermore, PHPQoL has all the elements re-
quired to become a suitable questionnaire for both routine
clinical practice and research: it has few items, is easily
understandable by the patient, and contains short ques-
tions and response categories. The definitive scoring sys-
tem and clinically relevant thresholds will be determined in
the validation phase of the study, which is already under-
way. The current version of the PHPQoL also has good
preliminary measurement properties.
Up to date, the impact of PHPT on patients’ HRQoL has
been measured using generic questionnaires. The advan-
tage of disease specific questionnaires versus generic ones
is that the former allow assessing the impact of specific,
often exclusive, aspects of a disease and its treatment on
patient’s daily lives. While studies performed in PHPT
patients with generic questionnaires, such as the SF-36
[13,15], have shown that surgery and other treatments
improve HRQoL of symptomatic patients, particularly in
aspects related to vitality, social functioning, general health,






domain of V.2 of the
PHPQoL questionnaire)
(Emotional functioning




No. of items 16 9 7 34
Score distribution Valid observation 61 66 62 55
Mean 58.73 58.08 59.10 63.2
SD 21.95 25.49 20.82 19.70
25th percentile 43.75 38.89 42.86 50.74
50th percentile 57.81 55.56 60.71 66.18
75th percentile 76.56 77.78 78.57 80.88
Total item correlation 0.45-0.81 0.66-0.84 0.57-0.77 0.03-0.81
Internal consistency (Cronbach’s alpha) 0.92 0.91 0.82 0.96
Rasch analysis
Person separation 3.06 2.87 2.23 3.72
Person reliability 0.90 0.89 0.83 0.93
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ory loss or attention deficit cannot be evaluated using
these instruments.
Other existing questionnaires are largely used in clinical
practice to measure the severity of the symptoms, but these
questionnaires do not link the severity of symptoms with
their impact on a patient’s daily life. An example of this is
the Pasieka’s parathyroid symptoms score, which evaluates
the severity of PHPT symptoms and detects changes after
surgery [35]. Other questionnaires are the Beck Depression
Inventory which measures neuropsychological symptoms
such as anxiety, depression, and memory problems, the
Hamilton Anxiety and Depression scale [36], the North
American Adult Reading Test [37], and the Rey Auditory
Verbal Learning Test [38] to evaluate HRQoL, but none of
these questionnaires is specific or was designed to evaluate
PHPT patients.
One of the interests of those specialists who treat PHPT
patients is the impact of their treatments on the HRQoL in
symptomatic and apparently asymptomatic patients. The
HRQoL described in this manuscript appears capable of
serving that function. Up to date the majority of studies
have concluded that both quality of life and neuropsycho-
logical symptoms improve after surgery [12,14,39], but
HRQoL has been measured through generic question-
naires. The disease specific HRQoL PHPT questionnaire
will be a useful tool in clinical practice to understand the
impact of treatment on patients’ daily life.
Results of the pilot study (67 patients) showed no sig-
nificant differences in scores depending on whether or
not the patients had undergone surgery or had been
treated for kidney stones, but the sample of patientstreated with kidney stones was very small. It is to be
expected that a larger sample of patients with kidney
stones, would show differences between patients with
and without symptoms in terms of HRQoL.
Only preliminary data are available on the measure-
ment properties of the PHPQoL questionnaire. A valid-
ation study is currently underway involving a large
sample of PHPT patients with the aim of determining
the measurement properties of this questionnaire such
as validity, reliability and sensitivity to change.
In conclusion, these results suggest that the described
HRQoL questionnaire is useful for defining the impact
of PHPT on the HRQoL of these patients.
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